Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Key Points: Genetic deletion of JAK2 in vivo shows that MPN cells remain fully dependent on JAK2 signaling for survival. Dual JAK2 targeting with JAK and HSP90 inhibitors offers increased efficacy in murine models and primary samples.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 3×
“Despite the important clinical benefits of ruxolitinib therapy, JAK inhibition with ruxolitinib and with other JAK inhibitors does not substantively reducemutant allele burden as is observed with BCR-ABL kinase inhibition in CML.(7) Similar results have been observed in murine models of MPN driven by activated Jak2/Mp…”
BackgroundInfluential
Cited by
Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells
Reichel, J., Chadburn, A., Rubinstein, P. G., Giulino-Roth, L., Tam, W., Liu, Y., Gaiolla, R., Eng, K., Brody, J., Inghirami, G., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610436 · Cited by 337
Myeloproliferative neoplasm stem cells
Mead, A. J., & Mullally, A. (2017) · Blood · doi:10.1182/blood-2016-10-696005 · Cited by 169
Koschmieder, S., Mughal, T. I., Hasselbalch, H. C., Barosi, G., Valent, P., Kiladjian, J.-J., Jeryczynski, G., Gisslinger, H., Jutzi, J. S., Pahl, H. L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.12 · Cited by 161
Pinto, B., Morelli, G., Rastogi, M., Savardi, A., Fumagalli, A., Petretto, A., Bartolucci, M., Varea, E., Catelani, T., Contestabile, A., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.09.010 · Cited by 135
“This solution was injected subcutaneously to animals with a dosage of 50mg/kg twice a day from P20 to P22 (Bhagwat et al., 2014).”
MethodAustin, R. J., Straube, J., Bruedigam, C., Pali, G., Jacquelin, S., Vu, T., Green, J., Gräsel, J., Lansink, L., Cooper, L., et al. (2020) · Leukemia · doi:10.1038/s41375-019-0638-y · Cited by 61
Metadata
- Authors
- Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K., Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K., Taldone, T., Bradner, J. E., Chiosis, G., & Levine, R. L.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2014-03-27
- Volume
- 123
- Issue
- 13
- Pages
- 2075-2083
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1976156018
- Cited by
- 110
- References
- 4
- FWCI
- 7.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1182/blood-2014-01-547760
- The paper
- Bhagwat, N., Koppikar, P., Keller, M., Marubayashi, S., Shank, K., Rampal, R., Qi, J., Kleppe, M., Patel, H. J., Shah, S. K., Taldone, T., Bradner, J. E., Chiosis, G., & Levine, R. L. (2014). Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood-2014-01-547760
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.